{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:45:33Z","timestamp":1792601133198,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"DOI":"10.1007\/s40256-026-00830-8","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:16:50Z","timestamp":1792599410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Conventional Antihypertensives: RNA Interference, Endothelin Antagonism, and Aldosterone-Synthase Inhibition in the Current Therapeutic Landscape"],"prefix":"10.1007","author":[{"given":"Giovanni Vincenzo","family":"Gaudio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tremamondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-0449","authenticated-orcid":false,"given":"Alessandro","family":"Lupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"38","key":"830_CR1","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"key":"830_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","volume":"126","author":"R Kreutz","year":"2024","unstructured":"Kreutz R, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1\u201315. https:\/\/doi.org\/10.1016\/j.ejim.2024.05.033.","journal-title":"Eur J Intern Med"},{"issue":"6","key":"830_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jama.2023.28539","volume":"331","author":"GL Bakris","year":"2024","unstructured":"Bakris GL, et al. RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA. 2024;331(6):521\u201332. https:\/\/doi.org\/10.1001\/jama.2023.28539.","journal-title":"JAMA"},{"issue":"1","key":"830_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jama.2025.6681","volume":"334","author":"AS Desai","year":"2025","unstructured":"Desai AS, et al. Add-on treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial. JAMA. 2025;334(1):46\u201355. https:\/\/doi.org\/10.1001\/jama.2025.6681.","journal-title":"JAMA"},{"issue":"3","key":"830_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389(3):228\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2208391.","journal-title":"N Engl J Med"},{"issue":"6","key":"830_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacbts.2021.04.004","volume":"6","author":"ES Morgan","year":"2021","unstructured":"Morgan ES, Tami Y, Hu K, et al. Antisense inhibition of angiotensinogen with IONIS-AGT-LRx: results of phase 1 and phase 2 studies. JACC Basic Transl Sci. 2021;6(6):485\u201396. https:\/\/doi.org\/10.1016\/j.jacbts.2021.04.004.","journal-title":"JACC Basic Transl Sci."},{"issue":"10367","key":"830_CR7","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","volume":"400","author":"MP Schlaich","year":"2022","unstructured":"Schlaich MP, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(22)02034-7.","journal-title":"Lancet"},{"key":"830_CR8","unstructured":"U.S. Food and Drug Administration. TRYVIO (aprocitentan) prescribing information. Revised April 2025. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217686s000lbl.pdf. Accessed on 7 Oct 2026."},{"key":"830_CR9","unstructured":"European Medicines Agency. Jeraygo (aprocitentan) EPAR; EU marketing authorisation granted 27 June 2024. Available from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jeraygo. Accessed on 7 Oct 2026."},{"key":"830_CR10","unstructured":"Medicines and Healthcare products Regulatory Agency. Aprocitentan approved to treat adults with hypertension whose blood pressure cannot be controlled by other medications. 17 January 2025. Available from https:\/\/www.gov.uk\/government\/news\/aprocitentan-approved-to-treat-adults-with-hypertension-whose-blood-pressure-cannot-be-controlled-by-other-medications. Accessed on 7 Oct 2026."},{"issue":"5","key":"830_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2213169.","journal-title":"N Engl J Med"},{"issue":"14","key":"830_CR12","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, BaxHTN Investigators, et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N Engl J Med. 2025;393(14):1363\u201374. https:\/\/doi.org\/10.1056\/NEJMoa2507109.","journal-title":"N Engl J Med"},{"key":"830_CR13","unstructured":"European Society of Cardiology. KARDIA-3 trial examines blood-pressure-lowering effects of zilebesiran in hypertensive patients at high cardiovascular risk. ESC Congress 2025 Madrid, Spain, press release, 30 August 2025. Available from https:\/\/www.escardio.org\/news\/press\/press-releases\/KARDIA-3-trial-examines-blood-pressure-lowering-effects-of-zilebesiran-in-hypertensive-patients-at-high-cardiovascular-risk\/. Accessed on 7 Oct 2026."},{"key":"830_CR14","unstructured":"ClinicalTrials.gov. Zilebesiran in patients with hypertension at high risk for cardiovascular events (ZENITH). NCT07181109. Available from https:\/\/clinicaltrials.gov\/study\/NCT07181109. Accessed on 7 Oct 2026."},{"issue":"6","key":"830_CR15","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1161\/HYPERTENSIONAHA.124.22878","volume":"81","author":"D Ye","year":"2024","unstructured":"Ye D, et al. Counteracting angiotensinogen small-interfering RNA-mediated antihypertensive effects with REVERSIR. Hypertension. 2024;81(6):e132\u20135. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.22878.","journal-title":"Hypertension"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00830-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00830-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00830-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:16:52Z","timestamp":1792599412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00830-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":15,"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00830-8","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Giovanni Vincenzo Gaudio, Giuseppe Derosa, Giuseppe De Angelis, John Tremamondo, and Alessandro Lupi declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Contributions are reported according to the CRediT (Contributor Roles Taxonomy) framework. Giovanni Vincenzo Gaudio: conceptualization, writing\u2014original draft (sections: Introduction, Angiotensinogen as Therapeutic Target, and Clinical Evidence for Zilebesiran), and writing\u2014review and editing. Giuseppe Derosa: conceptualization, writing\u2014original draft (sections: Competing and Complementary Emerging Therapies, and Comparative Overview), and writing\u2014review and editing. Giuseppe De Angelis: writing\u2014original draft (sections: Safety and Implementation Considerations, ZENITH Trial, Critical Interpretation) and writing\u2014review and editing. John Tremamondo: writing\u2014review and editing (language and copy editing). Alessandro Lupi: conceptualization, writing\u2014original draft (sections: Future Perspectives and Conclusions), and writing\u2014review and editing, supervision, and correspondence.","order":2,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated for this manuscript.","order":3,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}